45 Cytostatic drugs

Side Effects of Drugs Annual

Volumn 29, Issue , 2007, Pages 551-572

  Lipp, Hans Peter ^a   Hartmann, Jörg Thomas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34248673141     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(06)29045-7     Document Type: Review

References (142)

1. Kantarjian H.M., Gandhi V., Kozuch P., Faderl S., Giles F., Cortes J., O'Brien S., Ibrahim N., Khuri F., Du M., Rios M.B., Jeha S., McLaughlin P., Plunkett W., and Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 6 (2003) 1167-1173
2. Gandhi V., and Plunkett W. Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol 18 6 (2006) 584-590
3. Chiao N., Bumgardner A., and Duvic M. Clofarabine-induced acral erythema during the treatment of patients with myelodysplasia and acute leukemia: report of two cases. Leukemia Lymphoma 44 (2003) 1405-1407
4. Weinshilboum R.M. Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica 9 10 (1992) 1055-1071
5. Kröplin T., Weyer N., Gutsche S., and Iven H. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 54 (1998) 265-271
6. Kennedy D.T., Hayney M.S., and Lake K.D. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 30 (1996) 951-954
7. Yates C.R., Krynetski E.Y., Loennechen T., Fessing M.Y., Tai H.L., Pui C., Relling M.V., and Evans W.E. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126 (1997) 608-614
8. Escousse A., Rifle G., Sgro C., Mousson C., Zanetta G., and Chevet D. Azathioprine toxicity, 6-mercaptopurine accumulation and the "poor" 6-thiopurine methylator phenotype. Eur J Clin Pharmacol 48 (1995) 309-310
9. Evans W.E., Hon Y.Y., Bomgaars L., Coutre S., Holdsworth M., Janco R., Kalwinsky D., Keller F., Khatib Z., Margolin J., Murray J., Quinn J., Ravindranath Y., Ritchey K., Broberts W., Rogers Z.R., Schiff D., Steuber C., Tucci F., and Kornegay N. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 19 (2001) 2293-2301
10. Nygaard U., Toft N., and Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 4 (2004) 274-281
11. Lewis L.D., Benin A., Szumlanski C.L., Otterness D.M., Lennard L., Weinshilboum R.M., and Nierenberg D.W. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 62 (1997) 464-475
12. Geller S.A., Dubinsky M.C., Poordad F.F., Vasiliauskas E.A., Cohen A.H., Abreu M.T., Tran T., Martin P., Vierling J.M., and Targan S.R. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-tioguanine therapy in inflammatory bowel disease. Am J Surg Pathol 28 9 (2004) 1204-1211
13. Kontorinis N., Agarwal K., Gondolesi G., Fiel M.I., O'Rourke M., and Schiano T.D. Diagnosis of 6 mercaptopurine hepatotoxicity post liver transplantation utilizing metabolite assays. Am J Transplant 4 9 (2004) 1539-1542
14. Marinaki A.M., Sumi S., Arenas M., Fairbanks L., Harihara S., Shimizu K., Ueta A., and Duley J.A. Allele frequency of inosine triphosphate pyrophosphatase gene polymorphisms in a Japanese population. Nucleosides Nucleotides Nucleic Acids 23 8-9 (2004) 1399-1401
15. Thomsen J.B.O., Schröder H., Kristinsson J., Madson B., Szumlanski C., Weinshilboum R., Andersen J.B., and Schmiegelow K. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells. Cancer 86 (1999) 1080-1086
16. Cohen R.D. Sperm, sex, and 6-MP: the perception on conception. Gastroenterology 127 4 (2004) 1263-1264
17. Norgard B., Pedersen L., Jacobsen J., Rasmussen S.N., and Sorensen H.T. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 19 6 (2004) 679-685
18. Moskovitz D.N., Bodian C., Chapman M.L., Marion J.F., Rubin P.H., Scherl E., and Present D.H. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99 4 (2004) 656-661
19. Russmann S., and Lauterburg B. Lebensbedrohliche Nebenwirkungen der Gichtbehandlung. Life-threatening adverse effects of pharmacologic antihyperuricemic therapy. Ther Umsch 61 9 (2004) 575-577
20. Barnes B.H., Borowitz S.M., Saulsbury F.T., Hellems M., and Sutphen J.L. Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine. J Pediatr Gastroenterol Nutr 38 5 (2004) 509-512
21. Silverman L.R., Demakos E.P., Peterson B.L., Bercedis L.P., Kornblith A.B., Holland J.C., Odchimar-Reissig R., Stone R.M., Nelson D., Powell B.L., DeCastro C.M., Ellerton J., Larson R.A., Schiffer C.A., and Holland J.F. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 10 (2002) 2429-2440
22. Marcucci G., Silverman L., Eller M., Lintz L., and Beach C.L. Biovailability of azacytidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 45 (2005) 597-602
23. Adams C.D., Szumita P.M., Baroletti S.A., and Lilly C.M. Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome. Pharmacotherapy 25 (2005) 765-768
24. Malet-Martino M., and Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7 (2002) 288-323
25. Scheithauer W., McKendrick J., Begbie S., Borner M., Burns W.I., Burris H.A., Cassidy J., Jodrell D., Koralewski P., Levine E.L., Marschner N., Maroun J., Garcia-Alfonso P., Tujakowski J., Van Hazel G., Wong A., Zaluski J., and Twelves C. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14 (2003) 1735-1743
26. Segalla J., van Eyll B., Federico M., Perdicaris M., Cabral S., Skare N., Saltz E., Moura G., Filho U., and Franke F. Evaluation of quality of life (QoL) in patients with metastatic colorectal cancer treated with capecitabine. Proc ASCO 23 (2005) A8090
27. Schmoll H.J. Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. Anti-Cancer Drugs 14 (2003) 695-702
28. Saif M.W., Wood T.E., McGee P.J., and Diasio R.B. Peripheral neuropathy associated with capecitabine. Anti-Cancer Drugs 15 (2004) 767-771
29. Frickhofen N., Beck F.J., Jung B., Fuhr H.G., Andrasch H., and Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 13 (2002) 797-801
30. Pirzada N.A., Ali I.I., and Dafer R.M. Fluorouracil-induced neurotoxicity. Ann Pharmacother 34 (2000) 35-38
31. Abushullaih S., Saad E.D., Munsell M., and Hoff P.M. Hand-foot syndrome commonly associated with capecitabine. Cancer Invest 1 (2002) 3-10
32. Okuda H., Ogura K., Kato A., Takubo H., and Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Pharmacology 2 (1998) 791-799
33. Damon L.E., Mass R., and Linker C.A. The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 10 (1989) 1563-1568
34. Richards C., and Wujcik D. Cutaneous toxicity associated with high-dose cytosine arabinoside. Oncol Nurs Forum 19 (1992) 1191-1195
35. Hermans C., Straetmans N., and Michaux J.L. Pericarditis induced by high-dose cytosine arabinoside chemotherapy. Ann Hematol 75 (1997) 55-57
36. Gähler A., Hitz F., Hess U., and Cerny T. Acute pericarditis and pleural effusion complicating cytarabine chemotherapy. Onkologie 26 (2003) 348-350
37. Patel M., Ezzat W., Pauw K.L., and Lowsky R. Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and chemotherapy. Eur J Haematol 67 (2001) 318-321
38. Rubin E.H., Andersen J.W., Berg D.T., Schiffer C.A., Mayer R.J., and Stone R.M. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol 6 (1992) 948-953
39. Herzig R.H., Hines J.D., Herzig G.P., Wolff S.N., Cassileth P.A., Lazarus H.M., Adelstein D.J., Brown R.A., Coccia P.F., Strandjord S., Mazza J.J., Fay J., and Pillips G.L. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 6 (1987) 927-932
40. Vogel H., and Horoupian D.S. Filamentous degeneration of neurons. Cancer 71 (1993) 1303-1308
41. Smith G.A., Damon L.E., Rugo H.S., Ries C.A., and Linker C.A. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 2 (1997) 833-839
42. Openshaw H., Slatkin N.E., Stein A.S., Hinton D.R., and Forman S.J. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 78 (1996) 1899-1905
43. Gottliebe D., Bradstock K., Koutts J., Robertson T., Lee C., and Castaldi P. The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer 60 (1987) 1439-1441
44. Crawford S.M., Rustin G.J.S., and Bagshawe K.D. Acute neurological toxicity of intrathecal cytosine arabinoside. Cancer Chemother Pharmacol 16 (1986) 306-307
45. Planer D., Cukierman T., Liebster D., Ilsar M., and Chajek-Shaul T. Anterior uveitis as a complication of treatment with high dose cytosine-arabinoside. Am J Hematol 76 (2004) 304-306
46. Tanaka M., Kanamori H., Yamaji S., Mishima A., Fujita H., Fujisawa S., Murate T., Koharazawa H., Matsuzaki M., and Mohri H. Low-dose cytarabine-induced hepatic and renal dysfunction in a patient with myelodysplastic syndrome. Anti-Cancer Drugs 10 (1999) 289-291
47. Cetkovska P., Pizinger K., and Cetkovsky P. High-dose cytosine arabinoside-induced cutaneous reactions. J Eur Acad Dermatol Venereol 16 (2002) 481-485
48. Crawford J.H., Eikelboom J.W., and McQuillan A. Recurrent palmar-plantar erythrodysesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia. Eur J Haematol 69 (2002) 315-317
49. Glantz M.J., Jaeckle K.A., Chamberlain M.C., Phuphanich S., Recht L., Swinnen L.J., Maria B., LaFollette S., Schumann G.B., Cole B.F., and Howell S.B. A randomized controlled trial comparing intrathecal sustained-release cytarabine (Depocyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 11 (1999) 3394-3402
50. Kantarjian H.M., O'Brien S., Cortes J., Giles F.J., Faderl S., Issa J.P., Garcia-Manero G., Rios M.B., Shan J., Andreeff M., Keatin M., and Talpaz M. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98 (2003) 522-528
51. Kuhn J.G. Fluorouracil and the new oral fluorinated pyrimidines. Ann Pharmacother 35 (2001) 217-227
52. Bleiberg H. Continuing the fight against advanced colorectal cancer: new and future treatment options. Anti-Cancer Drugs 9 (1998) 18-28
53. Oettle H., Meyer L., Bechstein W.O., and Riess H. 5-Fluorouracil: synchronous application of continuous and bolus therapy in heavily pretreated metastatic colorectal cancer: a phase I/II study. Onkologie 23 (2000) 128-132
54. Weh H.J., Wilke H.J., Dierlamm J., Klaassen U., Siegmund R., Illiger H.J., Schalhorn A., Kreuser E.D., Hilgenfeld U., Steinke B., Weber W., Burkhard O., Zoller A., Pfitzner J., Subert R., Kriebel R., and Hossfeld D.K. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 5 (1994) 233-237
55. Larsson P.A., Carlsson G., Gustavsson B., Graf W., and Glimelius B. Different intravenous administration techniques for 5-fluorouracil. Acta Oncol 2 (1996) 207-212
56. Käfer G., Achtnich M., Willer A., Weiss A., and Queißer W. Cardiotoxicity in 5-fluorouracil/folinic acid treatment for metastatic colorectal cancer. Onkologie 21 (1998) 324-327
57. Anand A.J. Fluorouracil cardiotoxicity. Ann Pharmacother 28 (1994) 374-378
58. Lemaire L., Malet-Martino M.C., de Forni M., and Lasserre M. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 66 (1992) 119-127
59. Lieutaud T., Brain E., Golgran-Toledano D., Vincent F., Cvitkovic E., Leclercq B., and Escudier B. 5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure. Eur J Cancer 32A 2 (1996) 368-369
60. Südhoff T., Enderle Md., Pahlke M., Petz C., Teschendorf C., Graeven U., and Schmiegel W. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 15 (2004) 661-664
61. Cianci G., Morelli M.F., Cannita K., Ricevuto E., Morese R., Di Rocco Z.C., Porzio G., Baldi Lanfluti P., and Ficorella C. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer 88 (2003) 1507-1509
62. Takimoto C.H., Zhi-Hong L., Zhang R., Liang M.D., Larson L.V., Cantilena L.R., Grem J.L., Allegra C.J., Diasio R.B., and Chu E. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2 (1996) 477-481
63. Tebbutt N.C., Norman A.R., Cunningham D., Allen M., Chau I., Oates J., and Hill M. Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. Br J Cancer 88 (2003) 1510-1515
64. Berg D. Managing the side effects of chemotherapy for colorectal cancer. Semin Oncol 5 (1998) 53-59
65. Fleming G.F., Schilsky R.L., Schumm L.P., Meyerson A., Hong A.M., Vogelzang N.J., and Ratain M.J. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leukovorin in patients with organ dysfunction. Ann Oncol 14 (2003) 1142-1147
66. Diasio R.B., Beavers T.L., and Carpenter J.T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81 1 (1988) 47-51
67. Di Paolo A., Danesi R., Cionini L., Falcone A., Vannozzi F., Masi G., Allegrini G., Mini E., Bocci G., Conte P.F., and Del Tacca M. Relationship between 5-fluorouracil disposition toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 12 (2001) 1301-1306
68. Diasio R.B., and Johnson M.R. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 5 (1999) 2672-2673
69. Beuzeboc P., Pierga J.Y., Stoppa-Lyonnet D., Etienne M.C., Milanoe G., and Pouillart P. Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta. Eur J Cancer 32A (1996) 369-370
70. Van Kuilenburg A., Meinsma R., Zonnenberg B.A., Zoetekouw L., Baas F., Matsuda K., Tamaki N., and van Gennip A.H. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 9 (2003) 4363-4367
71. Sloan J., Goldberg R.M., Sargent D.J., Vargas-Chanes D., Nair S., Cha S.S., Novotny P.J., Poon M.A., and O'Connell Loprinzi C.L. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20 (2002) 1491-1498
72. Sloan J.A., Loprinzi C.L., Novotny P.J., Okuno S., Nair S., and Barton D.L. Sex differences in fluorouracil-induced stomatitis. J Clin Oncol 18 (2000) 412-420
73. Comandone A., Bretti S., La Grotta G., Manzoni S., Bonardi G., Berardo R., and Bumma C. Palmar-plantar erythrodysesthesia syndrome associated with 5-fluorouracil treatment. Anticancer Res 13 (1993) 1781-1784
74. Gamelin E., Boisdron-Celle M., Delva R., Regimbeau C., Cailleux P.E., Alleaume C., Aaillet Ml., Goudier M., Sire M., Person-Joly M.C., Maigre M., Maillart P., Fety R., Burtin P., Lortholary A., Dumesnil Y., Picon L., Geslin J., Gesta P., Danquechin-Dorval E., Larra F., and Robert J. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 16 (1998) 1470-1478
75. Coudert B., Focan C., Donato di Paola E., and Levi F. It's time for chronotherapy. Eur J Cancer 38 (2002) 50-53
76. Kudrik F.J., Rivera M.P., Molina P.L., Maygarden S., and Socinski M.A. Hypersensitivity pneumonitis in advanced non-small-cell lung cancer patients receiving gemcitabine and paclitaxel: report of two cases and a review of the literature. Clin Lung Cancer 4 (2002) 52-56
77. Pavlakis N., Bell D.R., Millward M.J., and Levi J.A. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 80 (1997) 286-291
78. Rube C.E., Wilfert F., Uthe D., König J., Liu L., Schuck A., Willich N., Remberger K., and Rube C. Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother Oncol 72 (2004) 231-241
79. Storniolo A.M., Allerheiligen S., and Pearce H.L. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 24 Suppl 7 (1997) 72-77
80. Ulrich-Pur H., Kornek G.V., Roderer M., Haider K., Kwasny W., Depisch D., Greul R., Schneeweiss B., Krauss G., Funovics J., and Scheithauer W. A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer 88 (2000) 2505-2511
81. Green M.R. Gemcitabine safety overview. Semin Oncol 10 (1996) 32-35
82. Lewin S.N., Mutch D.G., Whitcomb B.P., Liapis H., and Herzog T.J. Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol 97 (2005) 228-233
83. Schwartz B.M., Khuntia D., Kennedy A.W., and Markmann M. Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy. Gynecol-Oncol 91 (2003) 421-422
84. Venook A.P., Egorin M.J., Rosner G.L., Hollis D., Mani S., Hawkins M., Byrd J., Hohl R., Budman D., Meropol N.J., and Ratain M.J. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and leukemia group B 9565. J Clin Oncol 14 (2000) 2780-2787
85. Kopp H.G., Kanz L., Moerike K., and Hartmann J.T. Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomide. Clin Pharmacol Ther 78 (2005) 89-90
86. Townsley C.A., Chi K., Ernst D.S., Belanger K., Tannock I., Bjarnason G.A., Stewart D., Goel R., Ruether J.D., Siu L.L., Jolivet J., McIntosh L., Seymour L., Moore M.J., and National Cancer Institute of Canada-Clinical Trials Group. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 21 (2003) 1524-1529
87. Giles F.J., Cortes J.E., Baker S.D., Thomas D.A., O'Brien S., Smith T.L., Beran M., Bivins C., Jolivet J., and Kantarjian H.M. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 19 (2001) 762-771
88. Belanger K., Moore M., Baker S.D., Dionne J., Maclean M., Jolivet J., Siu L., Soulieres D., Wainman N., and Seymour L. Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. J Clin Oncol 10 (2002) 2567-2574
89. Hui Y.F., Giles F.J., and Cortes J.E. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome-recall following different chemotherapy agents. Investig New Drugs 20 (2002) 49-53
90. Roberts J.D., Poplin E.A., Tombes M.B., Kyle B., Spicer D.V., Grant S., Synold T., and Moran R. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol 45 (2000) 103-110
91. Takami M., Kuniyoshi Y., Oomukai T., Ishida T., and Yamano Y. Severe complications after high-dose methotrexate treatment. Acta Oncologica 34 (1995) 611-612
92. Aquerreta I., Aldaz A., Giraldez J., and Sierrasesumaga L. Pharmacodynamics of high-dose methotrexate in pediatric patients. Ann Pharmacother 36 (2002) 1344-1350
93. Quinn C.T., Griener J.C., Bottiglieri T., Hyland K., Farrow A., and Kamen B.A. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 15 (1997) 2800-2806
94. Doroshow J.H., Locker G.Y., Gaasterland D.E., Hubbard S.P., Young R.C., and Myers C.E. Ocular irritation from high-dose methotrexate therapy. Cancer 48 (1981) 2158-2162
95. Alarcon G.S., Kremer J.M., Macaluso M., Weinblatt M.E., Cannon G.W., Palmer W.R., St. Clair E.W., Sundy J.S., Alexander R.W., Smith W., and Axiotis C.A. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. Ann Intern Med 127 (1997) 356-364
96. Bokemeyer C., Scholtissek M., Schmoll H.-J., and Poliwoda H. Anaphylactoid type reaction in a patient receiving high-dose methotrexate chemotherapy. Onkologie 15 (1992) 313-316
97. Shamash J., Earl H., and Souhami R. Acetazolamide for alkalinisation of urine in patients receiving high-dose methotrexate. Cancer Chemother Pharmacol 28 (1991) 150-151
98. Widemann B.C., Balis F.M., Bielack-Kempf B., Bielack S., Pratt C.B., Ferrari S., Bacci G., Craft A.W., and Adamson P.C. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100 (2004) 2222-2232
99. Peyriere H., Cociglio M., Margueritte G., Vallat C., Blayac J.P., and Hillaire-Buys D. Optimal management of methotrexate intoxication in a child with osteosarcoma. Ann Pharmacother 38 (2004) 422-427
100. Lee A.C.W., Wong K.W., Fong K.W., and So K.T. Intrathecal methotrexate overdose. Acta Paediatr 86 (1997) 434-437
101. Widemann B.C., Balis F.M., Shalabi A., Boron M., O'Brien M., Cole D.E., Jayaprakash N., Ivy P., Castle V., Muraszko K., Moertel C.L., Trueworthy R., Hermann R.C., Moussa A., Hinton S., Reaman G., Poplack D., and Adamson P.C. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxy-peptidase G2. JNCI 96 (2004) 1557-1559
102. Moore T.J., Walsh C.S., and Cohen M.R. Reported medication errors associated with methotrexate. Am J Health-Syst Pharm 61 (2004) 1380-1384
103. Cohen I.J. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol 26 (2004) 156-163
104. Adjei A. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 10 (2004) 4276-4280
105. Hazarika M., White R.M., Booth B.P., Wang Y.C., Lee Ham D.Y., Liang C.Y., Rahman A., Gobburu J., Li N., Sridharar R., Morse D.E., Lostritto R., Garvey P., Johnson J.R., and Pazdur R. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11 (2005) 982-992
106. Rusthoven J.J., Eisenhauer E., Butts C., Gregg R., Dancey J., Fisher B., and Iglesias J. Multitargeted antifolate LY 231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 17 (1999) 1194-1199
107. Miles D.W., Smith I.E., Coleman R.E., Calvert A.H., and Lind M.J. A phase II study of pemetrexed disodium (LY 231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 37 (2001) 1366-1371
108. Chu E., Callender M.A., Farrell M.P., and Schmitz J.C. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 52 (2003) 80-89
109. Van Cutsem E., Cunningham D., Maroun J., Cervantes A., and Glimelius B. Raltitrexed: current clinical status and future directions. Ann Oncol 13 (2002) 513-522
110. Massacesi C., Santini D., Rocchi M., La Cesa A., Marcucci F., Vincenzi B., Delprete S., Tonini G., and Bonsignori M. Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors. Anti-Cancer Drugs 14 (2003) 533-541
111. Raderer M., Fiebiger W., Wrba F., and Scheithauer W. Fatal liver failure after the administration of raltitrexed for cancer chemotherapy. Cancer 89 (2000) 890-892
112. Blanke C.D., Kasimis B., Schein P., Capizzi R., and Kurman M. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 15 (1997) 915-920
113. Hum M., Holcenberg I.S., Tkacewski I., Weaver J.W., Wilson J., and Kamen B.A. High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection. Clin Cancer Res 4 (1998) 2981-2984
114. Smorenburg C.H., Seynaeve C., Bontenbal M., Planting A.S.Th., Sindermann H., and Verweij J. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. Anti-Cancer Drugs 11 (2000) 825-828
115. Leonard R., Hard J., van Tienhoven G., Houston S., Simmonds P., David M., and Mansi J. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol 21 (2001) 4150-4159
116. Cheson B.D. New antimetabolites in the treatment of human malignancies. Semin Oncol 19 (1992) 695-706
117. Johnson S.A. Clinical pharmacokinetics of nucleoside analogues. Clin Pharmacokinet 39 (2000) 5-26
118. Boogaerts M.A., Van Hoof A., Catovsky D., Kovacx M., Montillo M., Zinzani P.L., Binet J.L., Feremans W., Marcus R., Bosch F., Verhoef G., and Klein M. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 19 (2001) 4252-4258
119. Cheson B.D. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13 (1995) 2431-2448
120. Cheson B.D., Vena D.A., Foss F.M., and Sorensen J.M. Neurotoxicity of purine analogs: a review. J Clin Oncol 12 (1994) 2216-2228
121. Bishop M.K., Gelman C.R., Rumack B.H., and Hutchison T.A. Lack of toxicity in a cladribine extravasation. Ann Pharmacother 33 (1999) 873
122. Van Besien K., Devine S., Wickrema A., Jessop E., Amin K., Yassine M., Maynard V., Stock W., Peace D., Ravandi F., Chen Y.-H., Hoffman R., and Sossman J. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant 32 (2003) 471-476
123. Helman Jr. D.L., Byrd J.C., Ales N.C., and Shorr A.F. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest 122 (2002) 785-790
124. Trojan A., Meier R., Licht A., and Taverna C. Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma. Ann Hematol 81 (2002) 535-537
125. Gonzalez H., Bolgert F., Camporo P., and Leblond V. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther 41 (1999) 183-186
126. Cid J., Revilla M., Cervera A., Cervantes F., Munoz E., Ferrer I., and Montserrat E. Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol 79 (2000) 392-395
127. Anaissie E.J., Kontoyiannis D.P., O'Brien S., Kantarjian H., Robertson L., Lerner S., and Keating M.J. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129 (1998) 559-566
128. Ng H.J., and Lim L.C. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol 80 (2001) 549-552
129. Gandhi V., and Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41 (2002) 93-103
130. Mahadevan A., Kanegaonkar R., and Hoskin P.J. Third space sequestration increases toxicity of fludarabine. Acta Oncol 36 (1997) 441
131. Kane B.J., Kuhn J.G., and Roush M.K. Pentostatin: an adenosine deaminase inhibitor for the treatment of hairy cell leukemia. Ann Pharmacother 26 (1992) 939-947
132. Margolis J., and Grever M.R. Pentostatin (Nipent): a review of potential toxicity and its management. Semin Oncol 27 (2000) 9-14
133. Lathia C., Fleming G.F., Meyer M., Ratain M.J., and Whitfield L. Pentostatin pharmacokinetic and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol 50 (2002) 121-126
134. Huettemann E., Junker T., Chatzinikolaou K.P., Petrat G., Sakka S.G., Vogt L., and Reinhart K. The influence of anthracycline therapy on cardiac function during anesthesia. Br J Cancer 98 (2004) 941-947
135. c interval during isoflurane anaesthesia more prominent in women pretreated with anthracyclines for breast cancer?. Br J Anaesthesia 92 (2004) 658-661
136. Levitt G.A., Dorup I., Sorensen K., and Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity?. Br J Haematol 124 (2004) 463-468
137. Pein F., Sakiroglu O., Dahan M., Lebidois J., Merlet P., Shamsaldin A., Villain E., DeVathaire F., Sidi D., and Hartmann O. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 91 (2004) 37-44
138. Kopp H.G., Kanz L., and Hartmann J.T. Hypersensitivity pneumonitis associated with the use of trofosfamide. Anticancer Drugs 15 6 (2004) 603-604
139. Marr K.A., Leisenring W., Crippa F., Slattery J.T., Corey L., Boeckh M., and McDonald G.B. Cyclophosphamide metabolism is affected by azole antifungals. Blood 103 (2004) 1557-1559
140. Gori S., Colozza M., Mosconi A.M., Franceschi E., Basurto C., Cherubini R., Sidoni A., Rulli A., Bisacci C., De Angelis V., Crino L., Crino L., and Tonato M. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 90 (2004) 36-40
141. Hiraki A., Aoe K., Murakami T., Maeda T., Eda R., and Takeyama H. Syndrome induced by paclitaxel in a patient with squamous cell carcinoma of the lung: a case report. Anticancer Res 24 (2004) 1135-1137
142. Kloover J.S., Den Bakker M.A., Gelderblom H., and Van Meerbeeck J.P. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 90 (2004) 304-305